Giuseppe MichieliNov 17, 2023
Higher-Dose #Fluvoxamine and Time to Sustained #Recovery in #Outpatients With #COVID19, JAMA: https://jamanetwork.com/journals/jama/fullarticle/2812204?guestAccessKey=54d3e80d-56e9-4898-af7f-16af89f61123&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=111723&adv=000003719403
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

This randomized study examines the effect of higher-dose fluvoxamine on time to sustained recovery from mild to moderate COVID-19 or progression to severe disease in nonhospitalized adults.

Giuseppe MichieliOct 28, 2023
The real-world #effectiveness of #fluvoxamine #therapy in mild to moderate #COVID19 patients https://pubmed.ncbi.nlm.nih.gov/37890224/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=10CQYG4wH40EtHVSNOD9mofMx7F21fnuzqLzNKyqhr7y2YTgCd&fc=None&ff=20231028121434&v=2.17.9.post6+86293ac #research
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) - PubMed

Fluvoxamine treatment is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19 and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation, necessitating careful consideration before prescribing the drug for COVID-19.

PubMed
Show threadVictoria Stuart 🇨🇦 🏳️‍⚧️Jun 16, 2023

Bramante CT et al. (2023) Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
The Lancet Infectious Diseases.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext

Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. ...

#ivermectin #fluvoxamine #SARSCoV2

Medisch ContactJan 13, 2023
Opnieuw geen bewijs dat #fluvoxamine werkt bij milde tot matige #covid. Ditmaal was de vraag of het middel tot sneller herstel leidt. #wetenschap #coronavirus https://www.medischcontact.nl/nieuws/laatste-nieuws/nieuwsartikel/fluvoxamine-zorgt-niet-voor-sneller-herstel-bij-milde-covid.htm?utm_source=twitter&utm_medium=coosto
Fluvoxamine zorgt niet voor sneller herstel bij milde covid

Twee keer daags 50 mg fluvoxamine leidde niet tot een sneller herstel na milde covid dan een placebo. Dat schrijven Matthew McCarthy e.a. in JAMA.

Giuseppe MichieliJan 13, 2023
McCarthy MW, Naggie S, Boulware DR, et al. Effect of #Fluvoxamine vs Placebo on Time to Sustained #Recovery in #Outpatients With Mild to Moderate #COVID19: A Randomized Clinical Trial. JAMA. Published online January 12, 2023. doi:10.1001/jama.2022.24100
Angela M. Reiersen, MD, MPENov 18, 2022
Intro with hashtags: I am a #psychiatrist & #epidemiologist. My research includes #neurodevelopment, #genetics, #epidemiology, & #longitudinalcourse of #ADHD, #Autism, #ASD, #ticDisorders, #TouretteSyndrome, #WolframSyndome, & #schizophrenia. Along with Dr. Eric Lenze, I ran the #StopCOVID #RCTs, which tested #fluvoxamine vs placebo for treatment of outpatients with early #COVID-19. We are also planning a trial of fluvoxamine for #longCOVID (protocol currently under review by IRB)...
Angela M. Reiersen, MD, MPENov 8, 2022
Intro with hashtags: I am a #psychiatrist & #epidemiologist. My research includes #neurodevelopment, #genetics, #epidemiology, & #longitudinalcourse of #ADHD, #Autism, #ASD, #ticDisorders, #TouretteSyndrome, #WolframSyndome, & #schizophrenia. Along with Dr. Eric Lenze, I ran the #StopCOVID #RCTs, which tested #fluvoxamine vs placebo for treatment of outpatients with early #COVID-19. We are also planning a trial of fluvoxamine for #longCOVID (protocol currently under review by IRB)...
Scientific FrontlineOct 21, 2022
There was no evidence of improvement in time to recovery in participants who took this dose of #fluvoxamine versus those who took a #placebo
#Covid19 #Medical #Pharmaceutical #sflorg
https://www.sflorg.com/2022/10/med10212201.html
Study Finds No Benefit to Taking Fluvoxamine for COVID-19 Symptoms

Fluvoxamine is one of three FDA-approved repurposed medications currently being tested in ACTIV-6.

ParleurNov 19, 2021
Je viens de trouver le profil Twitter du gars proche de #OneNation sur ma liste d’#IEF.
Dessus il y a tellement toute la panoplie du conspi biobio facho :
- de l’#antivax
- du RT France
- de l’anti-antivax qu’il a pris pour de l’antivax parce-que c’est une buse.
- une carte des chakras.
- des comparaisons non-vaccinés/juifs
- des citations de #DiVizio
- des citations d’#IdrissAberkane
- la promotion de la #fluvoxamine, de l’#ivermectine et de l’#hydroxychloroquine
- etc.
Tout à l’avenant.
Minnesota Fintech ☑️Jun 18, 2021

RT @Covid19Crusher@Twitter.com

The University of Minnesota trial of Fluvoxamine, Ivermectin and Metformin is ongoing and a researcher declares that, from preliminary findings:

"many people were having less extreme symptoms"

https://twitter.com/Covid19Crusher/status/1405886927283359753

--
Outpatient Treatment of SARS-CoV-2 With Ivermectin, Fluvoxamine, and Metformin:
https://www.clinicaltrials.gov/ct2/show/NCT04510194

--
RT @SajidJa23282468@Twitter.com

The UM trial design is designed to fail. Don't worry.

https://twitter.com/SajidJa23282468/status/1405955340567343109

#COVID19 #COVID #Corona #Ivermectin #Fluvoxamine

Covid19Crusher on Twitter

“The University of Minnesota trial of Fluvoxamine, Ivermectin and Metformin is ongoing and a researcher declares that, from preliminary findings,: "many people were having less extreme symptoms" https://t.co/4XNtem9raG”

Twitter